Skip to main content
Romualdo Barroso on Muck Rack

Romualdo Barroso

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Romualdo

Contact Romualdo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

|
By Ana C. Garrido-Castro, Noah Graham, Katelyn X. Li, Jett Crowdis, Kevin Bi, Jihye Park, Ricardo Garcia Pastorello, Yvonne Y. Li, Hersh V. Gupta, Thomas Kuntz, Russell Petry, Lincoln W. Pasquina, Ashka Patel, Molly DiLullo, Anna Frey, Merrida A Childress, Robert Wesolowski, Natalie Sinclair, Sarah Sinclair, Steve Lo, Nadine Tung, Peter Kaufman, Caroline Block, Wendy S. Chen, Kai W. Wucherpfennig, Ye Tian, Amy Williams Verified, Satabhisa Mukhopadhyay, Tathagata Dasgupta, Stuart J. Schnitt, Andrew D. Cherniack, Jennifer A. Ligibel, Nancy Lin, Elizabeth A. Mittendorf, Nabihah Tayob, Eliezer Van Allen, Sara M. Tolaney, Lynn Bi, Paulina Lange, Victoria Attaya, Meredith Faggen, Jeanna Walsh, Madhavi Toke, Romualdo Barroso
| Nature Verified
Abstract This multi-institutional randomized phase II clinical trial (NCT03414684) investigated the efficacy and safety of carboplatin plus nivolumab compared to carboplatin in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was progression-free survival (PFS) in a modified intention-to-treat (mITT) population of patients with chemotherapy-naïve (i.e., first-line) mTNBC.
Open in Who Shared Issue with article?
See all 1 articles